Результаты поиска

Лечение связанного с лекарствами остеонекроза челюсти с помощью клеточной терапии.

Введение: Остеонекроз челюсти (MRONJ), связанный с лекарственными препаратами, представляет собой серьезную проблему с учетом отсутствия «золотого стандартного» лечения. Клеточная терапия и тканевая инженерия предлагают перспективные терапевтические альтернативы. Цель этого исследования заключалась в использовании регенеративных свойств стромальной сосудистой фракции (AT-SVF) и лейкоцитного фибрина с высоким содержанием лейкоцита (L-PRF) для обработки MRONJ. AT-SVF содержит мезенхимальные стромальные клетки (MSC) и эндотелиальные клетки потомства (EPC), которые способствуют образованию костей,

Совпадение в полном тексте источника
… Several adjuvant therapies have been explored, including ozone therapy, hyperbaric oxygen (HBO), autofluorescence-guided bone surgery, pentoxifylline and tocopherol, human amniotic membrane (hAM) and autologous platelet concentrates (APC), with varying degrees of success ( Fortunato et al., 2020 ; Govaerts … Outcomes of a pharmacological protocol with pentoxifylline and tocopherol for the management of medication-related osteonecrosis of the jaws (MRONJ): a randomized study on 202 osteoporosis patients. J. Clin. Med. 12 (14), 4662. 10.3390/jcm12144662 De Santis G. C., de Macedo L. D., Orellana M. …

Oral Mucositis Induced By Anticancer Therapies.

Oral mucositis induced by conventional cytotoxic cancer therapies is a common and significant clinical problem in oncology. Mucositis symptoms, which include severe pain, may lead to dose reductions and unplanned interruptions of chemotherapy and/or radiotherapy, and often affect patients' quality of life. In addition, ulcerative mucositis represents a risk factor for local or systemic infectious complications that may be life-threatening in immunosuppressed patients. The development of biologically based targeted cancer therapies, which aim to block the growth, spread, and survival of tumors

Совпадение в полном тексте источника
… radiation therapy for HNC Level III Granulocyte-macrophage-colony-stimulating factor mouthwash Prevention of OM Patients receiving high-dose chemotherapy, for autologous or allogeneic HSCT Level II Misoprostol mouthwash Prevention of OM Patients receiving radiation therapy for HNC Level III Systemic pentoxifylline … therapy for HNC | Level III Granulocyte-macrophage-colony-stimulating factor mouthwash | Prevention of OM | Patients receiving high-dose chemotherapy, for autologous or allogeneic HSCT | Level II Misoprostol mouthwash | Prevention of OM | Patients receiving radiation therapy for HNC | Level III Systemic pentoxifylline …

Acute kidney injury in the patient with cancer.

Dramatic advances in the care of patients with cancer have led to significant improvement in outcomes and survival. However, renal manifestations of the underlying cancer as well as the effects of anti-neoplastic therapies leave patients with significant morbidity and chronic kidney disease risks. The most common renal manifestations associated with cancer include acute kidney injury (AKI) in the setting of multiple myeloma, tumor lysis syndrome, post-hematopoietic stem cell therapy, and AKI associated with chemotherapy. Knowledge of specific risk factors, modification of risk and careful atte

Совпадение в полном тексте источника
… Prevention and treatment include infusions of prostaglandin-E, pentoxifylline, and low-dose heparin [ 60 – 62 ]. Early administration of defibrotide, an antithrombotic and fibrinolytic agent, appears to beneficial, and if instituted early, may lead to improvements in GFR [ 63 , 64 ]. … Jolivet I Scrobohaci ML Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation Br J Haematol 1990 74 277 281 10.1111/j.1365-2141.1990.tb02583.x 2159315 62 Bianco JA Appelbaum FR Nemunaitis J Phase I-II trial of pentoxifylline …

Treatment of sarcoid granulomatous interstitial nephritis with adalimumab.

Sarcoidosis is a systemic disease with multiorgan involvement which can cause renal failure through several different mechanisms. Granulomatous interstitial nephritis is an important albeit less frequent cause of clinically significant renal disease. Herein, we present the case of a 46 year old woman with a history of sarcoidosis whom we evaluated for rapidly worsening kidney function and proteinuria. Renal biopsy revealed granulomatous interstitial nephritis. After therapy with adalimumab, her renal function improved with a significant reduction in proteinuria. Repeat kidney biopsy showed res

Совпадение в полном тексте источника
… These agents include nonspecific inhibitors of TNF-alpha release such as steroids, methotrexate, azathioprine, antimalarials, and phosphodiesterase inhibitors such as pentoxifylline and thalidomide. …

Management of Medication-Related Osteonecrosis of the Jaws With Hyperbaric Oxygen Therapy: A Case Report.

Medication-related osteonecrosis of the jaw (MRONJ) refers to the condition where the maxillary or mandibular bone becomes exposed and necrotic as a result of bisphosphonate therapy. The number of patients on bisphosphonates is increasing and so are the MRONJ cases. Since the initial data were published in the early 2000s, research into MRONJ has expanded significantly to enhance the understanding of this emerging condition. Various treatment options are available, but none have been established as the definitive "gold standard" for managing this disease. Hyperbaric oxygen therapy (HOT) is one

Совпадение в полном тексте источника
… The management strategies for MRONJ encompass a variety of treatments, including local oral care, pentoxifylline and tocopherol administration, ozone therapy, low-level laser therapy, platelet-rich plasma, parathyroid hormone, bone morphogenetic proteins, antibiotic therapy, and hyperbaric oxygen therapy …

Treatment-induced mucositis: an old problem with new remedies.

Mucositis may be a painful, debilitating, dose-limiting side-effect of both chemotherapy and radiotherapy for which there is no widely accepted prophylaxis or effective treatment. The basis of management is pain relief, prevention of dehydration and adequate nutrition. When tested vigorously, most antiseptic mouthwashes and anti-ulcer agents are ineffective. Simple mechanical cleansing by saline is the most effective traditional measure. A variety of new agents are effective. Granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) act outwith

Совпадение в полном тексте источника
… A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. 80 1 7 1995 36 42 Oral Surg Oral Med Oral Pathol Oral Radiol Endod 7552860 10.1016/s1079-2104(95)80014-x Wardley A. M. Scarffe J. H. …

Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.

BACKGROUND: Peripheral arterial disease (PAD) may cause occlusions (blockages) in the main arteries of lower limbs. One treatment option is … r aspirin and dipyridamole (ASA/DIP) versus placebo or nothing (six studies); ASA or ASA/DIP versus pentoxifylline (two studies); ASA/DIP versus indobufen (one study); ASA or ASA/DIP versus vitamin K antagonists (two studies); ASA/DIP versus low molecular weight heparin (one study); ticlopidine versus placebo (one study); ASA versus prostaglandin E1 (one study); …

Antioxidants for male subfertility.

BACKGROUND: Between 30% to 80% of male subfertility cases are considered to be due to the damaging effects of oxidative stress on sperm and 1 man in 20 will be affected by subfertility. Antioxidants are widely available and inexpensive when compared to other fertility treatments and many men are already using these to improve their fertility. It is thought that oral supplementation with antioxidants may improve sperm quality by reducing oxidative stress. Pentoxifylline, a drug that acts like an antioxidant, was also included in this review. OBJECTIVES: This Cochrane review aimed to evaluate t…

Radiotherapy and cytokines: A systems view of immunotherapy and toxicity (Review).

Radiotherapy (RT) is increasingly recognized as a system‑level immunomodulator capable of reshaping cytokine networks across spatial, temporal and dosimetric dimensions. This review synthesizes existing evidence on RT parameters, key signaling axes, major effector cells, organ‑specific contexts and clinical translation. It describes how the cyclic GMP‑AMP synthase/stimulator of interferon genes (STING)/IFN‑I, NF‑κB and TGF‑β pathways coordinate immune activation and immune suppression after irradiation. It then summarizes macrophage‑centered regulatory circuits and chemokine axes, including C‑

Совпадение в полном тексте источника
… Pentoxifylline inhibits TNF-α production and, when combined with vitamin E, can shorten mucositis duration ( 231 , 232 ). Recombinant human IL-11 (rhIL-11) has been evaluated to reduce ulcer severity and accelerate healing by promoting mucosal repair ( 233 , 234 ). …

Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series.

Medication-induced jaw osteonecrosis (MRONJ) is a rare and serious disease with a negative impact on patients' quality of life, whose exact cause remains unclear and which may have a multifactorial origin. Although there are different therapeutic protocols, there is still no consensus. This case series evaluated three patients diagnosed with staged 2 MRONJ treated at the University of Murcia dental clinic according to the protocols described by the Spanish Society of Oral and Maxillofacial Surgery and the American Association of Oral and Maxillofacial Surgeons. Within 12 months of the applicat

Совпадение в полном тексте источника
… The non-surgical treatment in stage 3 patients, consisting of systemic antibiotics, pentoxifylline 400 mg (which promotes blood circulation), tocopherol (vitamin E) IU twice daily and 0.12% chlorhexidine rinses four times daily, significantly improves pain, symptomatology and bone exposure [ 43 ]. … Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2019;128:491–497.e2. doi: 10.1016/j.oooo.2019.08.004. 44. Alons K., Kuijpers S.C.C., de Jong E., van Merkesteyn J.P.R. …

Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists.

BackgroundBone-targeted agents such as bisphosphonates and the RANKL antibody have revolutionised the care of patients with bone metastases. There has, however been increasing concern about the oral health of these patients and in particular osteonecrosis of the jaw (ONJ), especially with the increasing use of these agents at higher potencies for greater periods of time.MethodsA review of the published data in PubMed and meeting abstracts was performed to examine incidence, risk factors, pathogenesis, clinical course and management of osteonecrosis of the jaw with focus on cancer patients trea

Совпадение в полном тексте источника
… Pentoxifylline (blood viscosity reducer agent) and oral vitamin E has shown efficacy in a small case series [64] . … Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 110 2010 593 596 10.1016/j.tripleo.2010.05.067 20955948 65 Agrillo A. …

Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.

1. Humans are exposed in vivo to methylxanthines by dietary ingestion, as well as from their use as therapeutic agents. The inhibitory effect of a series of these compounds on high-affinity phenacetin O-deethylase activity in the human liver microsomal fraction, a measure of CYP1A2 activity, has been evaluated. 2. Paracetamol, the product of phenacetin O-deethylase activity, was analysed by gas chromatography/negative-ion mass spectrometry using a novel bistrifluoromethylbenzoyl/ trimethylsilyl derivative, and incubation conditions for assessing high-affinity phenacetin O-deethylase activity w

Medication-Related Osteonecrosis of the Jaw: A Systematic Review of Case Reports and Case Series.

Medication-related osteonecrosis of the jaw (MRONJ) is a rare condition, typically seen in patients receiving antiresorptive or antiangiogenic drugs. This study aims to synthesize reports and case series of MRONJ regarding sociodemographic and clinical characteristics and to evaluate the effectiveness of the treatments applied. Following PRISMA guidelines, a search for case reports and case series was carried out in the PubMed-Medline database until March 2024. A total of 88 articles were included in this review, in a total of 151 cases. The key findings reveal that females were the most affec

Совпадение в полном тексте источника
… In the same percentage of the population, a combination of pentoxifylline + tocopherol was administered, in unknown doses, and amniotic membrane was applied independently. … Of these, the L-PRF membrane, the amniotic membrane, and the pentoxifylline + tocopherol combination stand out, although there have also been fewer cases in which these treatments were not associated with curing the disease. …

The organization, weaknesses, and challenges of the control of thalidomide in Brazil: A review.

The drug thalidomide has resurged in the world market under restrictive conditions for marketing and use. In Brazil, there are still cases of pregnant women using thalidomide even after the implementation of laws that regulate the control of use (Law No. 10.651/2003 and Collegiate Board Resolution No. 11/2011). The objective of this study was to discuss the control of thalidomide use in Brazil, based on a scoping review of the scientific literature, documents, and data from the Ministry of Health. A total of 51 studies and documents related to the following subthemes were selected: (1) organiz

Совпадение в полном тексте источника
… Alternative therapies: prednisone and pentoxifylline. | Technical-operational manual provides guidelines for surveillance, attention, and elimination of leprosy as a public health problem [ 49 ]. | Consolidation Decree No. 2, 09/28/2017. … minimize the exposure risks to thalidomide embryopathy by instituting a PCDT for the treatment of ENH that allows the direction and unification of the use of thalidomide for this clinical condition, to establish criteria for treatment, also considering other already available drugs such as prednisone and pentoxifylline …

Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.

The prognosis of patients with systemic lupus erythematosus has greatly improved since treatment regimens combining corticosteroids and immunosuppressive medications have been widely adopted in therapeutic strategies given to these patients. Immune suppression is evidently efficient but also leads to higher susceptibility to infectious and malignant diseases. Toxic effects and sometimes unexpectedly dramatic complications of current therapies have been progressively reported. Identifying novel molecular targets therefore remains an important issue in the treatment of lupus. The aim of this rev

Совпадение в полном тексте источника
… In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. J Leuk Biol. 1995;57:242–249. doi: 10.1002/jlb.57.2.242. Galindo-Rodriguez G, Bustamante R, Esquivel-Nava G, Salazar-Exaire D, Vela-Ojeda J, Vadillo-Buenfil M, Avina-Zubieta JA. … Pentoxifylline in the treatment of refractory nephritic syndrome secondary to lupus nephritis. J Rheumatol. 2003;30:2382–2384. Sthoeger ZM, Zinger H, Mozes E. …

A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma.

Renal dysfunction is a common comorbidity of multiple myeloma. However, tumor lysis syndrome is a rare cause of renal dysfunction in multiple myeloma. Elotuzumab is a newly US FDA-approved monoclonal antibody used in the treatment of refractory multiple myeloma. To our knowledge, elotuzumab has not been associated with a case of tumor lysis syndrome. We present the case of a patient who developed clinical tumor lysis syndrome 1 week after treatment with elotuzumab accompanied by renal failure with hyperphosphatemia, hyperkalemia, and profound hyperuricemia. His course was further complicated b

Совпадение в полном тексте источника
… p.r.n., biotin 500 mg daily, calcium carbonate and vitamin D3 1,500 – 400 units b.i.d., codeine-guaifenesin 20 – 200 mg q.i.d. p.r.n., ferrous sulfate 325 mg daily, hydrocodone-acetaminophen 5 – 325 mg p.r.n., melatonin 3 mg QHS, multivitamins and vitamin B12 (doses unknown), omeprazole 20 mg b.i.d., pentoxifylline …

Oral complications in hematopoietic stem cell recipients: the role of inflammation.

Hematopoietic stem cell transplantation (HSCT) is widely used as a potentially curative treatment for patients with various hematological malignancies, bone marrow failure syndromes, and congenital immune deficiencies. The prevalence of oral complications in both autologous and allogeneic HSCT recipients remains high, despite advances in transplant medicine and in supportive care. Frequently encountered oral complications include mucositis, infections, oral dryness, taste changes, and graft versus host disease in allogeneic HSCT. Oral complications are associated with substantial morbidity and

Совпадение в полном тексте источника
… Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood. 1991;78(5):1205–1211. 25. Ferrà C, de Sanjosé S, Lastra CF, et al. … Effects of the tumour necrosis factor-α inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. European Journal of Oral Sciences. 2005;113(3):210–217. doi: 10.1111/j.1600-0722.2005.00216.x. 27. Freitas AP, Bitencourt FS, Brito GA, et al. …

Novel Cell Therapy Using Mesenchymal Stromal Cell Sheets for Medication-Related Osteonecrosis of the Jaw.

Despite medication-related osteonecrosis of the jaw (MRONJ) being first reported in 2003, the optimal treatment and prevention modalities for MRONJ are not clear. As a result, dentistry, oral surgery, and departments involved in the treatment of cancer and bone diseases are struggling with the management of MRONJ. Several cases of MRONJ cannot be managed by conventional treatment strategies recommended in various position papers. Therefore, studies have been conducted to investigate the efficacy of novel therapies for MRONJ. However, the optimal treatment is unknown. Several cell therapies inc

Совпадение в полном тексте источника
… In addition, the efficacies of various drugs and therapies such as platelet plasma, low-power laser irradiation, bone morphogenetic protein, pentoxifylline, and tocopherol have been investigated, but none of these have been clearly proven effective or widely implemented ( Kaibuchi et al., 2021 ). …

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal Diseases.

BackgroundSargramostim (yeast-derived, glycosylated recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) augments innate and adaptive immune responses and accelerates hematopoietic recovery of chemotherapy-induced neutropenia. However, considerably less is known about its efficacy as adjunctive immunotherapy against invasive fungal diseases (IFDs).MethodsThe clinical courses of 15 patients with pediatric malignancies and IFDs treated adjunctively with sargramostim at a single institution were analyzed in a retrospective cohort review. Further, a systematic review of

Совпадение в полном тексте источника
… Montgomery 1991 (Washington) [ 15 ] | 25 yo M | HD | Invasive cutaneous fungal infection ( C. albicans ) | Yes | Yes (prior amphotericin B) | Sargramostim 250 µg/m 2 /d x21 d | Amphotericin B, pentoxifylline | Marked relief in pain and erythema within several days of initiating therapy; complete response … Localization of transfused neutrophils to site of infection during treatment with recombinant human granulocyte-macrophage colony-stimulating factor and pentoxifylline. Blood 1991; 78:533–4. 16. Vazquez JA, Gupta S, Villanueva A. …

Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease.

BACKGROUND: Advanced chronic liver disease is characterised by a long compensated phase followed by a rapidly progressive 'decompensated' ph … virals, alcohol abstinence, nutrition, diuretics, β-blockers, selective intestinal decontamination, pentoxifylline, prednisolone, and other supportive measures depending on the clinical status and requirement) was administered equally to the trial groups. Very low-certainty evidence suggested a decrease in mortality with G-CSF, administered alone or in combinati …